QTERN (saxagliptin/dapagliflozin)

QTERN™ is a fixed dose combination of saxagliptin and dapagliflozin and is indicated in adults aged 18 years and older with type 2 diabetes mellitus1

Dosing and Cost

QTERN™ extends oral therapy with a once daily tablet to improve glycaemic control1

Keep metformin and replace Forxiga tablet with Qtern
Keep metformin and replace Forxiga tablet with Qtern

QTERN™ 28 tablets: £49.56 – a 27% reduction in price compared to monocomponents*1,11-13



QTERN™ continues the simplicity of a once-daily tablet1,6,8

*combined monocomponent price: £68.1911,12

FORXIGA® and QTERN™ are not indicated for the management of weight loss or high blood pressure. Weight change was a secondary endpoint in clinical trials.1,6

FORXIGA® and QTERN™ should not be initiated in patients with an eGFR <60 ml/min/1.73m2.1,6

FORXIGA® 10 mg is associated with low risk of hypoglycaemia when added to metformin. Insulin and insulin secretagogues, such as sulphonylureas, cause hypoglycaemia. Therefore, a lower dose of insulin or an insulin secretagogue may be required to reduce the risk of hypoglycaemia when used in combination with FORXIGA®.6

If QTERN™ is used in combination with insulin secretagogue (sulphonylurea), a reduction in the dose of sulphonylurea may be required to minimise the risk of hypoglycaemia.1

Caution should be exercised in patients for whom a FORXIGA®-induced drop in blood pressure could pose a risk, and also in patients with prior history of UTIs and GIs.6